Etodolac, a selective cyclooxygenase-2 inhibitor, induces apoptosis by activating caspases in human malignant rhabdoid tumor cells (FRTK-1)

Oncology Reports

Volumn 17, Issue 1, 2007, Pages 169-173

  Hakozaki, Michiyuki ^a   Hojo, Hiroshi ^a   Kikuchi, Shinichi ^a   Abe, Masafumi ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Apoptosis; Caspase; Cyclooxygenase 2 inhibitor; Etodolac; FRTK 1 cell line; Malignant rhabdoid tumor

Indexed keywords

BENZYLOXYCARBONYLVALYL ALANYL ASPARTYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLVALYL-ALANYL-ASPARTYL FLUOROMETHYL KETONE; CASPASE; CYCLOOXYGENASE 2 INHIBITOR; CYSTEINE PROTEINASE INHIBITOR; ETODOLAC; ISOENZYME; PEPTIDE CHLOROMETHYL KETONE;

APOPTOSIS; ARTICLE; DRUG EFFECT; ENZYME ACTIVATION; ENZYMOLOGY; HUMAN; METABOLISM; PATHOLOGY; PHYSIOLOGY; RHABDOID TUMOR; TUMOR CELL LINE;

AMINO ACID CHLOROMETHYL KETONES; APOPTOSIS; CASPASES; CELL LINE, TUMOR; CYCLOOXYGENASE 2 INHIBITORS; CYSTEINE PROTEINASE INHIBITORS; ENZYME ACTIVATION; ETODOLAC; HUMANS; ISOENZYMES; RHABDOID TUMOR;

EID: 39049181160     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.17.1.169     Document Type: Article

References (31)

1. Weeks DA, Beckwith JB, Mierau GW and Luckey DW: Rhabdoid tumor of kidney. A report of 111 cases from the National Wilms' Tumor Study Pathology Center. Am J Surg Pathol 13: 439-458, 1989. (Pubitemid 19149607)
2. Vane JR, Bakhle YS and Botting RM: Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 38: 97-120, 1998. (Pubitemid 28231490)
3. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB and Lipsky PE: Cyclooxygenase in biology and disease. FASEB J 12: 1063-1073, 1998. (Pubitemid 28418937)
4. Turini ME and DuBois RN: Cyclooxygenase-2: a therapeutic target. Annu Rev Med 53: 35-57, 2002. (Pubitemid 34177870)
5. Hazar B, Ergin M, Seyrek E, Erdogan S, Tuncer I and Hakverdi S: Cyclooxygenase-2 (Cox-2) expression in lymphomas. Leuk Lymphoma 45: 1395-1399, 2004. (Pubitemid 38701916)
6. Cetin M, Buyukberber S, Demir M, Sari I, Sari I, Deniz K, Eser B, Altuntas F, Camci C, Ozturk A, Turgut B, Vural O and Unal A: Overexpression of cyclooxygenase-2 in multiple myeloma: association with reduced survival. Am J Hematol 80: 169-173, 2005. (Pubitemid 41579537)
7. Dickens DS, Kozielski R, Khan J, Forus A and Cripe TP: Cyclooxygenase-2 expression in pediatric sarcomas. Pediatr Dev Pathol 5: 356-364, 2002.
8. Sutton KM, Wright M, Fondren G, Towle CA and Mankin HJ: Cyclooxygenase-2 expression in chondrosarcoma. Oncology 66: 275-280, 2004. (Pubitemid 38822796)
9. Yamashita H, Osaki M, Ardyanto TD, Osaki M, Yoshida H and Ito H: Cyclooxygenase-2 in human malignant fibrous histiocytoma: correlations with intratumoral microvessel density, expression of vascular endothelial growth factor and thymidine phosphorylase. Int J Mol Med 14: 565-570, 2004.
10. Raspollini MR, Amunni G, Villanucci A, Paglierani M and Taddei GL: Cyclooxygenase-2 expression in uterine leiomyosarcomas. J Chemother 16: 577-581, 2004.
11. Lassus P, Ristimaki A, Huuhtanen R, Tukiainen E, Andersson LC, Asko-Seljavaara S, Miettinen M, Blomqvist C, Haglund C and Bohling T: Cyclooxygenase-2 expression in human soft-tissue sarcomas is related to epithelial differentiation. Anticancer Res 25: 2669-2674, 2005. (Pubitemid 41044645)
12. Gately S and Li WW: Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin Oncol 31: 2-11, 2004. (Pubitemid 38879409)
13. Dickens DS and Cripe TP: Effect of combined cyclooxygenase-2 and matrix metalloproteinase inhibition on human sarcoma xenografts. J Pediatr Hematol Oncol 25: 709-714, 2003. (Pubitemid 37087507)
14. Yamashita H, Osaki M, Honjo S, Yoshida H, Teshima R and Ito H: A selective cyclooxygenase-2 inhibitor, NS-398, inhibits cell growth by cell cycle arrest in a human malignant fibrous histiocytoma cell line. Anticancer Res 23: 4671-4676, 2003. (Pubitemid 38173883)
15. Hakozaki M, Hojo H, Sato M, Kaneko Y, Watanabe N, Kikuchi S and Abe M: Establishment and characterization of a new cell line, FRTK-1, derived from human malignant rhabdoid tumor of the kidney, with overexpression of epidermal growth factor receptor and cyclooxygenase-2. Oncol Rep 16: 265-271, 2006.
16. Bajorath J: Analysis of Fas-ligand interactions using a molecular model of the receptor-ligand interface. J Comput Aided Mol Des 13: 409-418, 1999.
17. Liu XH, Yao S, Kirschenbaum A and Levine AC: NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res 58: 4245-4249, 1998. (Pubitemid 28450018)
18. Tang X, Sun YJ, Half E, Kuo MT and Sinicrope F: Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells. Cancer Res 62: 4903-4908, 2002. (Pubitemid 34984412)
19. Nzeako UC, Guicciardi ME, Yoon JH, Bronk SF and Gores GJ: COX-2 inhibits Fas-mediated apoptosis in cholangiocarcinoma cells. Hepatology 35: 552-559, 2002. (Pubitemid 34183958)
20. Li M, Wu X and Xu XC: Induction of apoptosis in colon cancer cells by cyclooxygenase-2 inhibitor NS398 through a cytochrome c-dependent pathway. Clin Cancer Res 7: 1010-1016, 2001. (Pubitemid 32708740)
21. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM and Chen CS: The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 275: 11397-11403, 2000. (Pubitemid 30212792)
22. Chan TA, Morin PJ, Vogelstein B and Kinzler KW: Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA 95: 681-686, 1998. (Pubitemid 28083803)
23. Mishima K, Nariai Y and Yoshimura Y: Etodolac, a selective cyclooxygenase-2 inhibitor, enhances carboplatin-induced apoptosis of human tongue carcinoma cells by down-regulation of FAP-1 expression. Oral Oncol 41: 77-81, 2005. (Pubitemid 39647123)
24. Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K and DuBois RN: Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 23: 254-266, 2005. (Pubitemid 46206877)
25. Lippman SM, Gibson N, Subbaramaiah K and Dannenberg AJ: Combined targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways. Clin Cancer Res 11: 6097-6099, 2005. (Pubitemid 41262933)
26. Tortora G, Caputo R, Damiano V, Melisi D, Bianco R, Fontanini G, Veneziani BM, De Placido S, Bianco AR and Ciardiello F: Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. Clin Cancer Res 9: 1566-1572, 2003. (Pubitemid 36418415)
27. Chen Z, Zhang X, Li M, Wang Z, Wieand HS, Grandis JR and Shin DM: Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck. Clin Cancer Res 10: 5930-5939, 2004. (Pubitemid 39180975)
28. Zhang X, Chen ZG, Choe MS, Lin Y, Sun SY, Wieand HS, Shin HJ, Chen A, Khuri FR and Shin DM: Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clin Cancer Res 11: 6261-6269, 2005. (Pubitemid 41262957)
29. Melisi D, Caputo R, Damiano V, Bianco R, Veneziani BM, Bianco AR, De Placido S, Ciardiello F and Tortora G: Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. Endocr Relat Cancer 12: 1051-1058, 2005. (Pubitemid 41815796)
30. Kuwahara Y, Hosoi H, Osone S, Kita M, Iehara T, Kuroda H and Sugimoto T: Antitumor activity of gefitinib in malignant rhabdoid tumor cells in vitro and in vivo. Clin Cancer Res 10: 5940-5948, 2004. (Pubitemid 39180976)
31. Moalic-Juge S, Liagre B, Duval R, Corbiere C, Bianchi A, Bordji K, Bosgiraud C and Beneytout JL: The anti-apoptotic property of NS-398 at high dose can be mediated in part through NF-kappaB activation, hsp70 induction and a decrease in caspase-3 activity in human osteosarcoma cells. Int J Oncol 20: 1255-1262, 2002.